Recent Research | Page 78 | Aplastic Anemia and MDS International Foundation

Recent Research

Compiled for your convenience are the latest articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology. Articles are obtained from the National Library of Medicine’s MEDLINE database and date back to 2010.

Article Titlesort ascending Original Publication Date Journal Bone Marrow Disease
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes Jan 2012 Leuk Res myelodysplastic syndromes (MDS)
A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia Feb 2014 Int J Hematol aplastic anemia
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials Oct 2016 Leukemia myelodysplastic syndromes (MDS)
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Jul 2017 Cancer myelodysplastic syndromes (MDS)
5-Azacytidine for the treatment of myelodysplastic syndromes. Apr 2013 Expert Opin Pharmacother myelodysplastic syndromes (MDS)
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials Feb 2012 Leuk Lymphoma myelodysplastic syndromes (MDS)
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Sep 2014 Blood aplastic anemia
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution Sep 2014 Blood aplastic anemia
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study May 2014 Eur J Haematol myelodysplastic syndromes (MDS)
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy Feb 2017 Oncotarget myelodysplastic syndromes (MDS)